- Home
- MHN vs CLLS Comparison
MHN vs CLLS Comparison
Compare MHN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MHN | CLLS |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.6M | 299.0M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | MHN | CLLS |
|---|---|---|
| Price | $10.39 | $4.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 59.2K | ★ 138.2K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $8.69 | $1.10 |
| 52 Week High | $10.81 | $5.48 |
Technical Indicators
Market Signals| Indicator | MHN | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 58.54 |
| Support Level | $10.23 | $4.52 |
| Resistance Level | $10.51 | $4.92 |
| Average True Range (ATR) | 0.09 | 0.29 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 49.15 | 56.90 |
Price Performance
Historical ComparisonAbout MHN Blackrock MuniHoldings New York Quality Fund Inc.
BLACKROCK MUNIHOLDINGS NEW YORK QUALITY FUND, INC. is a closed-ended management investment company. The fund's investment objective is to provide shareholders with current income exempt from federal income tax and New York State and New York City personal income taxes.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.